|
|
10275 Science Center Drive San Diego, CA 92121 USA phone:1 858 550-7500 fax:1 858 550-7506
|
|
| Symbol |
LGND |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.ligand.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| New drugs that address critical unmet medical needs. |
 |
| Management |
| John L. Higgins, President and CEO; Martin D. Meglasson, PhD, Vice President, Discovery Research; Zofia E. Dziewanowska, MD, PhD, Vice President, Clinical Research; Syed Kazmi, PhD, MBA, Vice President, Business Development and Strategic Planning; John P. Sharp, Vice President, Finance and CFO; Charles Berkman, JD, Vice President, General Counsel and Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| oncology, cancer, dermatology, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular, inflammatory diseases, gene transcription technology |
|
|
|
| Description |
|
Ligand Pharmaceuticals, Inc. discovers, develops and markets small molecule drugs to address critical, unmet medical needs. |
 |
| Products / Services |
Ligand markets four oncology and dermatology products in the United States ' ONTAK, Targretin capsules, Targretin gel and Panretin gel. Ligand's fifth and newest product, AVINZA, is a treatment for chronic, moderate-to-severe pain.
|
 |
| Technology / Differentiation |
| Ligand produced a diverse portfolio of technologies and assets across numerous therapeutic areas, drug targets, and industry partners. They offer investors an opportunity to spread their risk while investing in the increasingly complicated and unpredictable pharmaceutical industry. |
 |
 |
| Status |
| Ligand's network of major pharmaceutical partners is developing products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's robust R&D pipeline is based on the company's leadership in gene transcription technology. |
 |
|
|
|
|
|
|